Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19

NCT05341609 is registered in ClinicalTrials.gov with Vigonvita Life Sciences as lead sponsor.

NCT NCT05341609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05341609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19
Lead sponsor
Vigonvita Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
April 4, 2022
Completion date
May 31, 2022
Enrollment
822 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19